Carcinoma, Non-Small-Cell Lung
"Carcinoma, Non-Small-Cell Lung" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.
MeSH Number(s)
C04.588.894.797.520.109.220.249
C08.381.540.140.500
C08.785.520.100.220.500
Concept/Terms
Carcinoma, Non-Small-Cell Lung- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non Small Cell Lung
- Carcinomas, Non-Small-Cell Lung
- Lung Carcinoma, Non-Small-Cell
- Lung Carcinomas, Non-Small-Cell
- Non-Small-Cell Lung Carcinomas
- Non-Small Cell Lung Cancer
- Non-Small-Cell Lung Carcinoma
- Non Small Cell Lung Carcinoma
- Carcinoma, Non-Small Cell Lung
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Non-Small-Cell Lung".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Non-Small-Cell Lung".
This graph shows the total number of publications written about "Carcinoma, Non-Small-Cell Lung" by people in Harvard Catalyst Profiles by year, and whether "Carcinoma, Non-Small-Cell Lung" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 7 | 0 | 7 |
| 1994 | 16 | 4 | 20 |
| 1995 | 19 | 4 | 23 |
| 1996 | 15 | 3 | 18 |
| 1997 | 9 | 5 | 14 |
| 1998 | 17 | 1 | 18 |
| 1999 | 15 | 2 | 17 |
| 2000 | 12 | 3 | 15 |
| 2001 | 26 | 5 | 31 |
| 2002 | 17 | 4 | 21 |
| 2003 | 27 | 4 | 31 |
| 2004 | 32 | 4 | 36 |
| 2005 | 64 | 6 | 70 |
| 2006 | 49 | 12 | 61 |
| 2007 | 51 | 8 | 59 |
| 2008 | 71 | 6 | 77 |
| 2009 | 63 | 8 | 71 |
| 2010 | 78 | 8 | 86 |
| 2011 | 82 | 9 | 91 |
| 2012 | 80 | 14 | 94 |
| 2013 | 88 | 10 | 98 |
| 2014 | 103 | 17 | 120 |
| 2015 | 142 | 14 | 156 |
| 2016 | 133 | 20 | 153 |
| 2017 | 116 | 12 | 128 |
| 2018 | 154 | 11 | 165 |
| 2019 | 155 | 8 | 163 |
| 2020 | 149 | 13 | 162 |
| 2021 | 149 | 5 | 154 |
| 2022 | 133 | 3 | 136 |
| 2023 | 8 | 0 | 8 |
Below are the most recent publications written about "Carcinoma, Non-Small-Cell Lung" by people in Profiles.
-
Updates in pathology and molecular diagnostics to inform the evolving landscape of thoracic surgery and oncology. J Surg Oncol. 2023 Feb; 127(2):244-257.
-
Sublobar resections for lung cancer: Finally, some answers and some more questions? J Surg Oncol. 2023 Feb; 127(2):269-274.
-
Optimizing molecular testing of lung cancer needle biopsy specimens: potential solutions from an interdisciplinary qualitative study. Respir Res. 2023 Jan 17; 24(1):17.
-
Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. Cancer Discov. 2023 Jan 09; 13(1):98-113.
-
Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol. 2023 Jan 01; 9(1):40-50.
-
Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. JAMA Oncol. 2023 Jan 01; 9(1):51-60.
-
Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis. J Immunother Cancer. 2023 Jan; 11(1).
-
Usage of Radiotherapy With Osimertinib Plus Bevacizumab Versus Osimertinib for Untreated Patients With Nonsquamous NSCLC Harboring EGFR Mutations. J Thorac Oncol. 2023 Jan; 18(1):e3-e4.
-
A deep-learning model for transforming the style of tissue images from cryosectioned to formalin-fixed and paraffin-embedded. Nat Biomed Eng. 2022 12; 6(12):1407-1419.
-
A novel 4'-brominated derivative of fisetin induces cell cycle arrest and apoptosis and inhibits EGFR/ERK1/2/STAT3 pathways in non-small-cell lung cancer without any adverse effects in mice. FASEB J. 2022 12; 36(12):e22654.